CIAM
ARQT icon

Caitong International Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Caitong International Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.8K Buy
+1,689
New +$43.1K 0.01% 849
2025
Q2 		– Sell
-1,032
Closed -$16.1K – 1982
2025
Q1 		$16.1K Sell
1,032
-5,864
-85% -$82.6K 0.01% 787
2024
Q4 		$96.1K Buy
+6,896
New +$75.6K 0.09% 252

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caitong International Asset Management's ARQT Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Arcutis Biotherapeutics (ARQT) in Q1 2026: 1,689 shares worth $39.8K. The stake represents 0.01% of the portfolio and ranks #849 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in ARQT as recently as Q1 2025.

Caitong International Asset Management first reported a position in ARQT in Q4 2024 and has held it in 3 quarters since. The position peaked at $96.1K in Q4 2024. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Caitong International Asset Management held 1,689 shares of Arcutis Biotherapeutics worth $39.8K as of Q1 2026.
  • Arcutis Biotherapeutics was a new Caitong International Asset Management position in Q1 2026.
  • Arcutis Biotherapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #849 holding.
  • Caitong International Asset Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 3 quarters since.
  • Caitong International Asset Management's Arcutis Biotherapeutics position peaked at $96.1K in Q4 2024.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.